Prothena Corp Public (PRTA) Current Deferred Revenue (2021 - 2026)
Prothena Corp Public (PRTA) posted quarterly Current Deferred Revenue of $1.6 million for Q1 2026, down 82.84% year-over-year from $9.5 million in Q1 2025, and down 38.81% quarter-over-quarter from $2.7 million in Q4 2025.
Prothena Corp Public (PRTA) Current Deferred Revenue (2021 - 2026) Analysis & Trends
Prothena Corp Public's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 82.84% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 82.84% YoY), while the FY2025 annual figure was $2.7 million, down 69.9% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $1.6 million, down from $2.7 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $109.5 million in Q1 2022, with the low at $316000.0 in Q3 2023.
- The 5-year median for Current Deferred Revenue is $9.4 million (2023), against an average of $28.9 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue tumbled 96.73% in 2023, then jumped 2684.81% in 2024.
- Prothena Corp Public's Current Deferred Revenue stood at $11.4 million in 2022, then tumbled by 97.24% to $316000.0 in 2023, then surged by 2700.63% to $8.8 million in 2024, then sank by 69.9% to $2.7 million in 2025, then sank by 38.81% to $1.6 million in 2026.
- Business Quant data shows PRTA's Current Deferred Revenue at $1.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 620,000.00 |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.69 Mn |
| Jun 30, 2025 | 5.10 Mn |
| Mar 31, 2025 | 9.50 Mn |
| Dec 31, 2024 | 8.85 Mn |
| Sep 30, 2024 | 8.80 Mn |
| Jun 30, 2024 | 15.40 Mn |
| Mar 31, 2024 | 67.40 Mn |
| Sep 30, 2023 | 316,000.00 |
| Jun 30, 2023 | 92.50 Mn |
| Mar 31, 2023 | 9.32 Mn |
| Dec 31, 2022 | 11.44 Mn |
| Sep 30, 2022 | 9.67 Mn |
| Jun 30, 2022 | 108.20 Mn |
| Mar 31, 2022 | 109.50 Mn |
| Dec 31, 2021 | 7.66 Mn |
| Sep 30, 2021 | 7.21 Mn |
| Jun 30, 2021 | 110.20 Mn |